BOULDER, Colorado, USA | November 18, 2026
VitriVax, Inc., a vaccine development and formulation technology company, has announced the successful closing of an oversubscribed $87 million Series C financing to advance its investigational Lyme disease vaccine candidate into its first-in-human clinical trial and expand its broader vaccine development pipeline. The financing was co-led by F-Prime, NEA, RA Capital Management and Sanofi Ventures, with participation from Eli Lilly and Company and other existing investors. The funding represents a significant milestone in VitriVax’s transition from a vaccine technology platform company into a biotechnology company developing its own proprietary vaccine candidates. The investment will primarily support the clinical advancement of its lead Lyme disease program, which is based on the company’s proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform. The company also plans to expand its research and development activities across infectious diseases and next-generation vaccine technologies.
87 Million Financing Accelerates Lyme Vaccine Development
The newly secured $87 million Series C investment will support VitriVax’s lead vaccine candidate as it progresses toward its first-in-human clinical evaluation. Lyme disease is a tick-borne infectious disease caused by bacteria belonging to the Borrelia burgdorferi group and is among the most common vector-borne diseases in the United States and Europe. The disease can cause symptoms affecting the skin, joints, heart and nervous system, particularly when diagnosis and treatment are delayed.Despite the growing public health burden, there is currently no approved human Lyme disease vaccine available in the United States. Existing vaccine development efforts have focused on multi-dose treatment schedules requiring an initial series followed by seasonal booster doses. VitriVax aims to address some of these limitations through its investigational vaccine candidate, which is designed to provide broad protection with a potentially simplified dosing approach.The company’s lead program is built around a novel mechanism of action and is being developed using the ALTA® formulation technology. The latest financing follows its $17.25 million Series B round completed in September 2025, reflecting continued investor interest in vaccine innovation and the development of technologies that could improve global access to preventive healthcare.
ALTA Technology Targets Single-Dose and Thermostable Vaccines
VitriVax’s proprietary ALTA® platform is designed to improve vaccine formulation, antigen stability and immune response while potentially reducing the complexity of vaccine administration. The technology combines antigens and adjuvants through an atomic-layering approach to create formulations intended to support single-dose vaccine administration and improved thermostability.One of the platform’s key objectives is to reduce dependence on conventional cold-chain storage requirements, which can create significant logistical challenges when distributing vaccines in resource-limited regions. By improving the stability of vaccine components, the technology could potentially support wider distribution and accessibility.The platform is also designed to improve immunogenicity, reduce antigen and adjuvant requirements and potentially lower manufacturing costs. VitriVax has additionally expanded its ALTA technology into a novel mRNA delivery system that does not require lipid nanoparticles (LNPs). This development could provide another approach to improving the formulation and delivery of next-generation vaccines. However, these are intended platform capabilities, and their clinical benefits will require further evaluation.Beyond Lyme disease, the company is developing additional vaccine candidates targeting infectious diseases where improved stability, immune response and simplified dosing could offer meaningful advantages.
Strategic Partnerships and Global Vaccine Pipeline Expansion
VitriVax’s development strategy is supported by collaborations with several global health organizations and research partners. The company has existing vaccine development programs supported by the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense. These partnerships cover different infectious disease programs, including rabies, polio, HIV and melioidosis vaccine development.CEPI supports VitriVax’s rabies vaccine development program, while the Gates Foundation supports its work involving polio and HIV vaccines. The company’s melioidosis vaccine program receives support through the U.S. Defense Threat Reduction Agency (DTRA), which operates within the Department of Defense. VitriVax also has a multi-year contract with the U.S. Department of Defense supporting its vaccine research activities.The Series C financing also attracted participation from major pharmaceutical industry investors, including Sanofi Ventures and Eli Lilly and Company. F-Prime, NEA and RA Capital Management joined as co-leading investors alongside Sanofi Ventures. Their participation reflects growing financial interest in biotechnology platforms focused on infectious disease prevention and advanced vaccine formulation.Importantly, these financing participants are investors, while the Gates Foundation, CEPI and U.S. Department of Defense support separate vaccine development programs. The announcement does not establish a new direct co-development or licensing agreement between VitriVax and Sanofi or Lilly for the Lyme disease vaccine.The latest funding milestone positions VitriVax to advance its Lyme disease vaccine toward clinical evaluation, strengthen its proprietary ALTA® technology and expand its broader vaccine pipeline. The company’s progress toward first-in-human clinical testing and cGMP manufacturing readiness represents an important step in translating its vaccine research into potential clinical applications. Further clinical studies will be necessary to establish the safety, immunogenicity and protective effectiveness of its investigational vaccine candidates.
Source: VitriVax, Inc press release



